Cipla Sees Strong Profit Growth in Q4 2025 Amid Rising Sales
In a remarkable financial performance, Cipla, the prominent Indian pharmaceutical company based in Mumbai, reported a 30% increase in its consolidated net profit for the fourth quarter ending March 31, 2025. This surge brought their net profit to an impressive ₹1,222 crore, driven by robust sales across key markets including India, the United States, and Africa.
Revenue Growth Across Key Markets
Cipla’s total operational revenue climbed to ₹6,730 crore, compared to ₹6,163 crore during the same period last year. The company’s domestic sales contributed significantly to this growth:
- India: Revenue rose to ₹2,622 crore, reflecting an 8% year-on-year increase from ₹2,417 crore in Q4 FY24.
- North America: Revenue reached ₹1,919 crore, a modest 2% increase from ₹1,875 crore in the previous year.
- Africa: The company experienced a robust 20% growth in revenue, totaling ₹1,019 crore for the quarter.
Annual Performance for FY25
For the fiscal year 2025, Cipla reported a consolidated net profit of ₹5,272 crore, marking a noteworthy 28% increase compared to ₹4,122 crore in FY24. The company’s total revenue soared to ₹27,548 crore, up from ₹25,774 crore the previous year. Umang Vohra, Cipla’s Managing Director and Global CEO, emphasized the company’s commitment to expanding its core markets, enhancing flagship brands, and investing in future pipeline developments, while also addressing regulatory challenges.
Dividend Announcement for Shareholders
In light of these impressive results, Cipla’s board has declared a final dividend of ₹13 per share for FY25, along with a special dividend of ₹3 per share to celebrate the company’s 90th anniversary. This brings the total dividend payout to ₹16 per share, with a face value of ₹2 each.
Stock Market Reaction
Following the announcement, Cipla’s shares experienced a slight uptick, closing at ₹1,519.45, reflecting a 0.49% increase on the Bombay Stock Exchange (BSE).
With a clear focus on innovation and market expansion, Cipla continues to strengthen its position as a leader in the pharmaceutical industry, promising exciting prospects for both the company and its stakeholders in the year ahead.
